Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development
Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/
The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health.
“The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future,” said Ben Russell, CEO of Argenta.
Argenta will conduct the R&D activities from its locations in the United States and New Zealand and will use proprietary drug delivery technologies to develop what are expected to be the next generation of veterinary pharmaceutical products. Argenta and NovaQuest will look for commercialization partners as the project progresses.
“This is an historic milestone for Argenta and instrumental in advancing our commitment to deliver innovation to the animal health industry. I am excited to leverage our product development expertise, IP and technology to accelerate some of the many options available,” commented Edward McGruder, Global head of Research, Development and Innovation at Argenta.
For NovaQuest, a premier biopharma and life sciences investment firm with extensive experience in human health product financing, this represents their first expansion into a collaboration of this nature within the animal health industry.
“We are excited to enter into this collaboration with Argenta, a trusted global leader in the animal health industry. With this investment we expand NovaQuest’s commitment to funding innovation in animal health across a wide range of companies and products,” said Jonathan Tunnicliffe, Chief Investment Officer of NovaQuest.
“NovaQuest’s commitment to bringing innovation to the animal health industry, combined with Argenta’s unparalleled end-to-end development capabilities and expertise make this a truly exciting collaboration,” said Brian Axe, Managing Director at NovaQuest.
Both companies are eager to start this product development journey to help accelerate innovation in the animal health industry.
Wyrick Robbins Yates & Ponton LLP acted as legal counsel to NovaQuest.
About NovaQuest
Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. Leveraging the core platform, NovaQuest is expanding its strategy to bring much needed capital to the animal health industry. NovaQuest is actively evaluating and investing in opportunities across animal segments and geographies. For more information, please visit www.novaquest.com
About Argenta
Argenta is the only combined global contract research organization (CRO) and contract development and manufacturing organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta operates ‘from Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005132/en/
Contact information
For NovaQuest:
Philip Nunes
BackBay Communications
+1 617-391-0792
Phil.nunes@backbaycommunications.com
For Argenta:
Annemieke de Keijzer
+1 732-439-3446
globalcommunications@argentaglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SiAT Partners with Zeon to Launch Innovative SWCNT Conductive Paste, Enhancing Battery Fast Charging and Energy Density18.4.2024 10:00:00 EEST | Press release
SiAT, a leading Taiwan manufacturer of advanced nanomaterials for batteries, is excited to announce a strategic partnership with Japan's Zeon Corporation. This collaboration marks the introduction of single-walled carbon nanotube conductive paste. The product can replace or be combined with carbon black to serve as a conductive agent additive in Lithium-ion battery cathode/anode formulations, and also has wide applications in transparent films and EMI shielding. Zeon produces single-walled carbon nanotubes (SWCNT) that demonstrate unique properties, including high aspect ratio, high purity and high specific surface area. Zeon is one of the few earliest SWCNT manufacturers and has achieved mass production since 2015. CNT tends to undergo bundling and lack of dispersibility in aqueous and nonaqueous media. Nanomaterial dispersion has always been a difficult problem to overcome. SiAT has the unique technology know-how experience and production capacity in the application of nanomaterial d
NILIT Announces Strategic Expansions, Including a Joint Venture with Shenma in China18.4.2024 06:30:00 EEST | Press release
NILIT, the global leader in high-performance Nylon 6.6 fibers for the apparel industry and leader in sustainability, that owns the broadest line of sustainable Nylon 6.6 products, is announcing a new joint venture with Shenma Industry Co., Ltd. (hereinafter referred to as Shenma), a subsidiary of China Pingmei Shenma Group, a global leader in the industrial Nylon 6.6 market and a leading supplier to the automotive industry around the world. This new partnership represents a significant expansion of production capacity within China, also demonstrating NILIT’s ongoing commitment to support the growth of global customers and brands. This expansion is highlighted by multiple investments and cooperation designed to enhance production capabilities and deliver more innovative solutions to the textile industry. “We are pleased to unveil this new greenfield joint venture in China with Shenma to introduce differentiated state-of-the-art technologies to support the local market,” says Ilan Melame
The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report18.4.2024 02:01:00 EEST | Press release
A new report published today reveals that adult vaccination programmes can return up to 19 times their initial investment when the full spectrum of economic and societal benefits is valued. The 19x return is equivalent to up to USD 4,637 in net monetary benefits to society per individual full vaccination course. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417519822/en/ Learn more about the economic benefits of investing in adult immunisation programmes in a new study by the Office of Health Economics (OHE). Graphic: OHE The study, a first-of-its-kind analysis of adult immunisation programmes by the Office of Health Economics (OHE) and commissioned by IFPMA (1), looked at four adult vaccines across ten countries where they are available to determine the wider economic and social impact. Focusing on vaccines that protect against influenza (flu), pneumococcal disease, respiratory syncytial virus (RSV), and herpes zoster (
Saudi Arabia Highlights Investment Initiatives in Tourism at International Hospitality Investment Forum17.4.2024 20:51:00 EEST | Press release
The Saudi Ministry of Tourism is currently taking a prominent stage at the International Hospitality Investment Forum (IHIF), presenting a unique opportunity for global investors to dive into the thriving tourism landscape of the Kingdom. With the spotlight on the Tourism Investment Enablers Program (TIEP), that was recently announced, Saudi Arabia is aggressively pushing towards its Vision 2030 goal of being a top global tourism destination for investors and tourists alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417879947/en/ Mr. Mahmoud Abdullhadi, Deputy Minister of Destinations Enablement. (Photo: AETOSWire) This strategic presentation comes at a time when Saudi Arabia's tourism sector celebrates an incredible milestone of 100 million visitors in 2023, seven years ahead of schedule, marking a significant stride towards economic diversification and emphasizing the sector's growing contribution to the nationa
Kai Tak Sports Park Limited and ASM Global Begin Countdown to Unveiling of World’s Largest Sports Development in History17.4.2024 16:00:00 EEST | Press release
The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/ PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire) ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom